|
?:abstract
|
-
Objective: To evaluate if hormonal contraception affects illness severity in SARS-CoV2 positive women Design: Retrospective cohort study Materials and Methods: Chart review of reproductive age (12-49 yo) women who tested positive for SARS-CoV2 at a tertiary medical center from March 28-April 27, 2020 Exclusion criterion was pregnancy Women using hormonal contraception were compared to patients not using hormonal contraception Patients were not contacted to confirm contraception The primary outcome was hospital admission rate Secondary outcomes included a composite score for illness severity and clinical signs of infection (Table 1) Multivariable logistic regression was used to control for differences at baseline Results are reported as adjusted odds ratio (aOR) with a 95% confidence interval (CI) Calculated p values < 0 05 were statistically significant Results: A total of 2044 women were screened for SARS-CoV2 Of the 132 positive women, 46 used hormonal contraception: levonorgestrel IUD (n=9;19 6%), injectable progestin (n=2;4 35%), oral progestin (n=3;6 52%), oral contraceptive (n= 24;52 1%), transdermal patch (n=4;8 70%), vaginal ring (n=4;8 70%) and 86 did not use hormonal contraception The rate of hospitalization for SARS-CoV2 was low for users and non-users of hormonal contraception (2 3% vs 3 8%, respectively) and was not statistically different between groups There was no difference between the rate of symptoms and clinical signs of infection between groups Conclusions: Sex hormones may play a significant role in regulating immune response and can impact disease state We provide preliminary evidence that use of hormonal contraception does not have a significant effect on the illness severity in SARS-CoV2 as measured by hospitalization [Formula presented]
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}